Therapeutic reversal of immune exhaustion with anti-PD-1/programmed cell death ligand-1 (PD-L1)-targeted therapies induces responses in only 20% of patients with HCC.1 The gene discussed is PDCD1; the disease is hepatocellular carcinoma.